scholarly journals Safety of ovarian preservation in women with stage I epithelial ovarian cancer

2016 ◽  
Vol 141 ◽  
pp. 53
Author(s):  
S. Chatterjee ◽  
L. Chen ◽  
N.L. Jones ◽  
A. Buckley de Meritens ◽  
W.M. Burke ◽  
...  
Cancer ◽  
1989 ◽  
Vol 63 (6) ◽  
pp. 1070-1073 ◽  
Author(s):  
Holly H. Gallion ◽  
John R. van Nagell ◽  
Elvis S. Donaldson ◽  
Robert V. Higgins ◽  
Deborah E. Powell ◽  
...  

2018 ◽  
Vol 38 (11) ◽  
pp. 6507-6511 ◽  
Author(s):  
EDGAR PETRU ◽  
CAROLA HUBER ◽  
EVA SAMPL ◽  
JOSEF HAAS

Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1554
Author(s):  
Enrica Calura ◽  
Matteo Ciciani ◽  
Andrea Sambugaro ◽  
Lara Paracchini ◽  
Giuseppe Benvenuto ◽  
...  

Stage I epithelial ovarian cancer (EOC) represents about 10% of all EOCs. It is characterized by a complex histopathological and molecular heterogeneity, and it is composed of five main histological subtypes (mucinous, endometrioid, clear cell and high, and low grade serous), which have peculiar genetic, molecular, and clinical characteristics. As it occurs less frequently than advanced-stage EOC, its molecular features have not been thoroughly investigated. In this study, using in silico approaches and gene expression data, on a multicentric cohort composed of 208 snap-frozen tumor biopsies, we explored the subtype-specific molecular alterations that regulate tumor aggressiveness in stage I EOC. We found that single genes rather than pathways are responsible for histotype specificities and that a cAMP-PKA-CREB1 signaling axis seems to play a central role in histotype differentiation. Moreover, our results indicate that immune response seems to be, at least in part, involved in histotype differences, as a higher immune-reactive behavior of serous and mucinous samples was observed with respect to other histotypes.


2019 ◽  
Vol 134 (5) ◽  
pp. 1017-1026 ◽  
Author(s):  
Koji Matsuo ◽  
Hiroko Machida ◽  
Wataru Yamagami ◽  
Yasuhiko Ebina ◽  
Yoichi Kobayashi ◽  
...  

2017 ◽  
Vol 72 (12) ◽  
pp. 713-715
Author(s):  
Alexander Melamed ◽  
Anthony E. Rizzo ◽  
Roni Nitecki ◽  
Allison A. Gockley ◽  
Amy J. Bregar ◽  
...  

1991 ◽  
Vol 34 (2) ◽  
pp. 195-196
Author(s):  
RC Young ◽  
LA Walton ◽  
SS Ellenberg ◽  
HD Homesley ◽  
GD Wilbanks ◽  
...  

2009 ◽  
Vol 113 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Jamie N. Bakkum-Gamez ◽  
Debra L. Richardson ◽  
Leigh G. Seamon ◽  
Giovanni D. Aletti ◽  
Cecelia A. Powless ◽  
...  

1992 ◽  
Vol 47 (7) ◽  
pp. 491-492
Author(s):  
CATHERINE B. FINN ◽  
D. M. LUESLEY ◽  
E. J. BUXTON ◽  
G. R. BLACKLEDGE ◽  
K. KELLY ◽  
...  

1989 ◽  
Vol 44 (9) ◽  
pp. 696-698
Author(s):  
Holly H. Gallion ◽  
John R. Van Nagell ◽  
Elvis S. Donaldson ◽  
Robert V. Higgins ◽  
Deborah E. Powell ◽  
...  

2010 ◽  
Vol 28 (10) ◽  
pp. 1727-1732 ◽  
Author(s):  
Toyomi Satoh ◽  
Masayuki Hatae ◽  
Yoh Watanabe ◽  
Nobuo Yaegashi ◽  
Osamu Ishiko ◽  
...  

Purpose The objective of this study was to assess clinical outcomes and fertility in patients treated conservatively for unilateral stage I invasive epithelial ovarian cancer (EOC). Patients and Methods A multi-institutional retrospective investigation was undertaken to identify patients with unilateral stage I EOC treated with fertility-sparing surgery. Favorable histology was defined as grade 1 or grade 2 adenocarcinoma, excluding clear cell histology. Results A total of 211 patients (stage IA, n = 126; stage IC, n = 85) were identified from 30 institutions. Median duration of follow-up was 78 months. Five-year overall survival and recurrence-free survival were 100% and 97.8% for stage IA and favorable histology (n = 108), 100% and 100% for stage IA and clear cell histology (n = 15), 100% and 33.3% for stage IA and grade 3 (n = 3), 96.9% and 92.1% for stage IC and favorable histology (n = 67), 93.3% and 66.0% for stage IC and clear cell histology (n = 15), and 66.7% and 66.7% for stage IC and grade 3 (n = 3). Forty-five (53.6%) of 84 patients who were nulliparous at fertility-sparing surgery and married at the time of investigation gave birth to 56 healthy children. Conclusion Our data confirm that fertility-sparing surgery is a safe treatment for stage IA patients with favorable histology and suggest that stage IA patients with clear cell histology and stage IC patients with favorable histology can be candidates for fertility-sparing surgery followed by adjuvant chemotherapy.


Sign in / Sign up

Export Citation Format

Share Document